MaaT Pharma Aktie [WKN DE: A3C7A5 / ISIN: FR0012634822]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu MaaT Pharma

07.11.24		MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD (Businesswire)
05.11.24		MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes (Businesswire)
15.10.24		MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease (Businesswire)
19.09.24		MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update (Businesswire)
04.09.24		MaaT Pharma To Present and Participate in Investor and Medical Conferences in September (Businesswire)
02.07.24		MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT (Businesswire)
25.06.24		MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16 (Businesswire)
24.06.24		MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer (Businesswire)
15.05.24		MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros (Businesswire)
14.05.24		MaaT Pharma Launches a Global Offering of approximately 18 Million Euros (Businesswire)
07.05.24		MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024 (Businesswire)
15.04.24		MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event (Businesswire)
28.03.24		MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview (Businesswire)
12.03.24		MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference (Businesswire)
29.02.24		MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) (Businesswire)
12.12.23		MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations (Businesswire)
11.12.23		MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023 (Businesswire)
30.11.23		MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan (Businesswire)
09.11.23		MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results (Businesswire)
06.11.23		MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT (Businesswire)
02.11.23		MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference (Businesswire)
31.10.23		MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies (Businesswire)
26.10.23		MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013 (Businesswire)
26.09.23		MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update (Businesswire)
12.09.23		MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies (Businesswire)
07.09.23		MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation (Businesswire)
27.07.23		MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results (Businesswire)
26.07.23		MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD (Businesswire)
20.07.23		MaaT Pharma Joins Microbiome Therapeutics Innovation Group (Businesswire)
21.06.23		MaaT Pharma Announces New Appointments to the Board and Executive Team (Businesswire)
09.05.23		MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023 (Businesswire)
24.04.23		MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease (Businesswire)
11.04.23		MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting (Businesswire)
30.03.23		MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview (Businesswire)
27.03.23		MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe (Businesswire)
17.02.23		MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders (Businesswire)
27.01.23		MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux (Businesswire)
24.01.23		MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023 (Businesswire)
11.12.22		MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting (Businesswire)
10.12.22		MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting (Businesswire)
29.11.22		MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference (Businesswire)
08.11.22		MaaT Pharma Reports Cash and Revenues for Third Quarter 2022 (Businesswire)
07.11.22		MaaT Pharma Announces Participation in Scientific and Investor Conferences in November (Businesswire)
03.11.22		MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting (Businesswire)
04.10.22		MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology (Businesswire)
29.09.22		MaaT Pharma Publishes its Half Year Results and Provides a Business Overview (Businesswire)
08.09.22		MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September (Businesswire)
28.07.22		MaaT Pharma Reports Cash and Revenues for Second Quarter 2022 (Businesswire)
02.06.22		MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients (Businesswire)
24.05.22		MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022 (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

Krypto-Update: Diese fünf Kryptowährungen stehen derzeit im Fokus

Bitcoin überholt Silber: Kryptowährung auf Rekordkurs

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

Diese Aktien empfehlen Experten zu kaufen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	25.11.2024 18:45
Kaufwert:	EUR
	Hinzufügen Speichern